Equity Awards - Geron Corporation granted equity awards covering an aggregate of 966,000 shares of common stock, including stock options for 644,000 shares and restricted stock units (RSUs) for 322,000 shares to sixteen newly hired employees [1][2] - The stock options have an exercise price of $1.27 per share, equal to the closing price on the grant date, with a ten-year term and vesting over four years [2] - RSUs vest at a rate of 25% on each anniversary of the grant date, contingent on continued employment [2] Company Overview - Geron is a commercial-stage biopharmaceutical company focused on treating blood cancer, with its first-in-class telomerase inhibitor RYTELO® (imetelstat) approved in the US and EU for certain adult patients with lower-risk myelodysplastic syndromes [3] - The company is conducting a pivotal Phase 3 clinical trial of imetelstat for JAK-inhibitor relapsed/refractory myelofibrosis and other myeloid hematologic malignancies [3] - The mechanism of action involves inhibiting telomerase activity to reduce proliferation and induce death of malignant cells in the bone marrow [3]

Commercial Performance - RYTELO Q2 2025 sales reached $49 million[12] - There was an approximate 17% demand increase for RYTELO in Q2 2025 compared to Q1 2025[14] - Approximately 30% of new RYTELO patients starts are in the 1st and 2nd line of treatment[14] - RYTELO has secured favorable coverage policies for approximately 90% of covered lives[14] - Since approval, approximately 400 new ordering accounts have been added year-to-date[14] Clinical Development - The Phase 3 IMpactMF trial is expected to be 100% enrolled by the end of 2025[11, 22] - An interim analysis of the IMpactMF trial is expected in the second half of 2026, with the final analysis anticipated in the second half of 2028[22] Financial Status - The company's cash and marketable securities totaled $432.6 million as of June 30, 2025[25] - Q2 2025 total operating expenses were $61.5 million[25] - The company anticipates operating expenses in the range of $270 million to $285 million for 2025[25]